CAMBRIDGE, Mass., March 14, 2018 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that preliminary data from its Phase 1 clinical trial evaluating…